 LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 GLOBE NEWSWIRE -- Mereo BioPharma Group plc NASDAQ: MREO Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering of 34,500,000 American Depositary Shares ADSs at a public offering price of 2.90 per ADS. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be 100.1 million. In addition, Mereo has granted the underwriters a 30-day option to purchase up to 5,175,000 additional ADSs at the public offering price, less underwriting discounts and commissions. Each ADS represents five ordinary shares of Mereo. All of the ADSs in the offering will be sold by Mereo. The offering is expected to close on or about February 12, 2021, subject to the satisfaction of customary closing conditions. 